Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment

Neuroscience

Volumn 105, Issue 2, 2001, Pages 353-364

  Medhurst, A D ^a   Zeng, B Y ^b   Charles, K J ^a   Gray, J ^a   Reavill, C ^a   Hunter, A J ^a   Shale, J A ^b   Jenner, P ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Differential display; Gene expression; Nigral striatal pathway; TaqMan; Up regulation

Indexed keywords

CARBIDOPA; COMPLEMENTARY DNA; LEVODOPA; MESSENGER RNA; OXIDOPAMINE; PREPROENKEPHALIN; SECRETOGRANIN II; SECRETONEURIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN INJURY; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

ANIMALS; APOMORPHINE; CHROMOGRANINS; DNA, COMPLEMENTARY; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEVODOPA; MALE; NEOSTRIATUM; NEURONS; NEUROPEPTIDES; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SECRETOGRANIN II; SYMPATHOLYTICS; UP-REGULATION;

EID: 0035958713     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(01)00190-7     Document Type: Article

References (43)

1. Sustained dopamine release induced by secretoneurin in the striatum of the rat: A microdialysis study
2. Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease
3. Secretion of a chromaffin granule protein chromogranin from the adrenal gland after splanchnic stimulation
4. Induction of dopamine D3 receptor expression as a mechanism of behavioural sensitisation to levodopa
5. B2 receptor subunits in the central nervous system differs from that in peripheral tissues
6. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA
7. A receptor subunit gene expression in the rodent basal ganglia and thalamus
8. Differential display of genes expressed at the midbrain-hindbrain junction identifies sprouty2: An FGF8-inducible member of a family of intracellular FGF antagonists
9. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain
10. Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin
11. Rapid amplification of complementary DNA ends for generation of full-length complementary DNA: Thermal RACE
12. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
13. Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA
14. Real time quantitative PCR
15. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on prepreoenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
16. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
17. The localisation of somatostatin receptor 1 sst1 immunoreactivity in the rat brain using an N-terminal specific antibody
18. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP
19. Secretoneurin - A neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C)
20. Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretoganin II in various regions of rat brain
21. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
22. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridisation study
23. Distribution of secretoneurin, a peptide derived from secretogranin II, in rat brain: An immunocytochemical and radioimmunological study
24. Parkinson's disease
25. Success and problems of long-term levodopa therapy in Parkinson's disease
26. Practical aspects of the experimental design for differential display of transcripts obtained from complex tissues
27. The use of Taqman RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models
28. Identification of differentially expressed genes in dorsal root ganglia following partial sciatic nerve injury
29. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine
30. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats
31. 1 receptor mRNA levels in the caudate-putamen
32. The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumours
33. Secretoneurin releases dopamine from rat striatal slices: A biological effect of a peptide derived from secretogranin II (chromogranin C)
34. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae
35. Point mutations in AAUAAA and the poly(A) addition site: Effects on the accuracy and efficiency of cleavage and polyadenylation in vitro
36. Differential increases in chromogranins, but not synapsin I, in cortical neurons following spreading depression: Implications for functional roles and transmitter peptide release
37. Release of secretoneurin and noradrenaline from hypothalamic slices and its differential inhibition by calcium channel blockers
38. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions
39. Secretoneurin: A functional neuropeptide in health and disease
40. Effects of secretogranin II-derived peptides on the release of neurotransmitters monitored in the basal ganglia of the rat with in vivo microdialysis
41. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats
42. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, prepreoenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rats
43. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA